In this article, we will take a look at some of the best AI driven biotech stocks that are currently offering attractive upside potential. On June 4, CNBC reported that global biopharma mergers and acquisitions are on course for their strongest year since before the pandemic. This trend is primarily driven by looming patent expirations, improving public market conditions, and pharmaceutical companies’ efforts to strengthen their product pipelines. According to PitchBook data, biotech and pharmaceutical deal-making totaled $106 billion across 201 transactions through the reporting period in 2026, putting the industry on track to exceed $250 billion in deal value for the year if the current pace continues.
Strategic acquisitions and corporate add-ons continue to dominate activity, with drug discovery accounting for a significant share of deal flow. The average deal value increased from $365 million in 2025 to over $527 million in 2026. As pharmaceutical companies look for assets that are easy to incorporate into their current portfolios, acquisitions in the $1 billion to $5 billion range have remained particularly active.
Western pharmaceutical companies have looked to China for innovation, where there is still significant interest in acquiring biotech assets. The industry has also benefited from improved investor optimism, as evidenced by the biotech index XBI’s 50% increase over the previous 12 months and several successful IPOs, signaling a more active market environment. With that background, let’s explore our 10 Best AI Driven Biotech Stocks to Invest In.
everything possible/Shutterstock.com
Our Methodology
To identify relevant stocks for this article, we screened U.S.-listed biotech companies that are heavily leveraging artificial intelligence capabilities. Our search includes companies with market capitalizations above $2 billion and offering at least 60% upside potential, according to consensus, as of the June 5 close. Finally, we selected 10 stocks with the highest upside and ranked them in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Corcept Therapeutics Inc. (NASDAQ:CORT)
Corcept Therapeutics Inc. (NASDAQ:CORT) is one of the 10 best AI driven biotech stocks to invest in.
On June 8, Corcept Therapeutics Inc. (NASDAQ:CORT) revealed the latest data from Catalyst and Momentum trials during the American Diabetes Association’s 86th Scientific Sessions. The results show a crucial role of hypercortisolism in type 2 diabetes, which appears to be difficult to contain. Moreover, it also extends influence on resistant hypertension.
The data also indicated the potential of the cortisol modulation procedure. The company’s Chief Development Officer, Bill Guyer, expanded on the data by emphasizing that hypercortisolism seems to be a major driver of cardiometabolic conditions. He stated:
“Data consistently show that hypercortisolism is an underlying driver of treatment resistant cardiometabolic disease, including in patients receiving best-in-class therapies like GLP-1s. Data from CATALYST demonstrate that treatment with a cortisol modulator, such as Korlym, can be synergistic with GLP-1s or tirzepatide to help patients better control type 2 diabetes. It is our hope that this new research will lead to increased screening for hypercortisolism and improved treatment.”
Back on May 28, Canaccord Genuity increased its target price for Corcept Therapeutics Inc. (NASDAQ:CORT) from $110 to $135, which represents an adjusted upside potential of almost 77%. The firm reiterated a Buy rating on the stock.
Genuity attributed the revision to the company’s surprise announcement, where they intend to resubmit the NDA relating to relacorilant, which will be utilized to cure patients with hypercortisolism.
Corcept Therapeutics Inc. (NASDAQ:CORT) is a commercial-stage pharmaceutical company that is involved in developing therapies for severe conditions. These include endocrinologic, oncologic, metabolic, and neurologic disorders. It is developing medicines that target hyperglycemia, hypercortisolism, prostate cancer, and amyotrophic lateral sclerosis.
Hedge Fund Resource Center